BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

460 related articles for article (PubMed ID: 15565569)

  • 1. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial.
    Färkkilä M; Karvonen AL; Nurmi H; Nuutinen H; Taavitsainen M; Pikkarainen P; Kärkkäinen P
    Hepatology; 2004 Dec; 40(6):1379-86. PubMed ID: 15565569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study.
    Olsson R; Boberg KM; de Muckadell OS; Lindgren S; Hultcrantz R; Folvik G; Bell H; Gangsøy-Kristiansen M; Matre J; Rydning A; Wikman O; Danielsson A; Sandberg-Gertzén H; Ung KA; Eriksson A; Lööf L; Prytz H; Marschall HU; Broomé U
    Gastroenterology; 2005 Nov; 129(5):1464-72. PubMed ID: 16285948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective.
    Cullen SN; Rust C; Fleming K; Edwards C; Beuers U; Chapman RW
    J Hepatol; 2008 May; 48(5):792-800. PubMed ID: 18314215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis.
    Harnois DM; Angulo P; Jorgensen RA; Larusso NF; Lindor KD
    Am J Gastroenterol; 2001 May; 96(5):1558-62. PubMed ID: 11374699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. Belgian-Dutch PSC Study Group.
    van Hoogstraten HJ; Vleggaar FP; Boland GJ; van Steenbergen W; Griffioen P; Hop WC; van Hattum J; van Berge Henegouwen GP; Schalm SW; van Buuren HR
    Am J Gastroenterol; 2000 Aug; 95(8):2015-22. PubMed ID: 10950051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Primary sclerosing cholangitis: conventional and quantitative liver function tests during long-term therapy with ursodeoxycholic acid].
    Schönfeld J; Zotz R; Mahl M; Beste M; Breuer N; Goebell H
    Z Gastroenterol; 1996 Feb; 34(2):123-7. PubMed ID: 8659187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis.
    Triantos CK; Koukias NM; Nikolopoulou VN; Burroughs AK
    Aliment Pharmacol Ther; 2011 Oct; 34(8):901-10. PubMed ID: 21883323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis.
    Lindström L; Hultcrantz R; Boberg KM; Friis-Liby I; Bergquist A
    Clin Gastroenterol Hepatol; 2013 Jul; 11(7):841-6. PubMed ID: 23353641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A network meta-analysis of the efficacy and side effects of UDCA-based therapies for primary sclerosing cholangitis.
    Zhu GQ; Shi KQ; Huang GQ; Wang LR; Lin YQ; Braddock M; Chen YP; Zhou MT; Zheng MH
    Oncotarget; 2015 Sep; 6(29):26757-69. PubMed ID: 26378046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of cholestatic liver diseases with ursodeoxycholic acid].
    Boberg KM; Schrumpf E
    Tidsskr Nor Laegeforen; 1997 Sep; 117(23):3370-3. PubMed ID: 9411890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis.
    Angulo P; Batts KP; Therneau TM; Jorgensen RA; Dickson ER; Lindor KD
    Hepatology; 1999 Mar; 29(3):644-7. PubMed ID: 10051462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia.
    Lindström L; Boberg KM; Wikman O; Friis-Liby I; Hultcrantz R; Prytz H; Sandberg-Gertzén H; Sangfelt P; Rydning A; Folvik G; Gangsøy-Kristiansen M; Danielsson A; Bergquist A
    Aliment Pharmacol Ther; 2012 Feb; 35(4):451-7. PubMed ID: 22221173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ursodeoxycholic acid and methotrexate for primary sclerosing cholangitis: a pilot study.
    Lindor KD; Jorgensen RA; Anderson ML; Gores GJ; Hofmann AF; LaRusso NF
    Am J Gastroenterol; 1996 Mar; 91(3):511-5. PubMed ID: 8633500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis.
    Wunsch E; Trottier J; Milkiewicz M; Raszeja-Wyszomirska J; Hirschfield GM; Barbier O; Milkiewicz P
    Hepatology; 2014 Sep; 60(3):931-40. PubMed ID: 24519384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials.
    Shi J; Wu C; Lin Y; Chen YX; Zhu L; Xie WF
    Am J Gastroenterol; 2006 Jul; 101(7):1529-38. PubMed ID: 16863557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of pretransplantation ursodeoxycholic acid therapy on the outcome of liver transplantation in patients with primary biliary cirrhosis.
    Heathcote EJ; Stone J; Cauch-Dudek K; Poupon R; Chazouilleres O; Lindor KD; Petz J; Dickson ER; Poupon RE
    Liver Transpl Surg; 1999 Jul; 5(4):269-74. PubMed ID: 10388499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis.
    Lindor KD; Kowdley KV; Luketic VA; Harrison ME; McCashland T; Befeler AS; Harnois D; Jorgensen R; Petz J; Keach J; Mooney J; Sargeant C; Braaten J; Bernard T; King D; Miceli E; Schmoll J; Hoskin T; Thapa P; Enders F
    Hepatology; 2009 Sep; 50(3):808-14. PubMed ID: 19585548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ursodeoxycholic acid and artesunate in the treatment of severe falciparum malaria patients with jaundice.
    Treeprasertsuk S; Silachamroon U; Krudsood S; Huntrup A; Suwannakudt P; Vannaphan S; Wilairatana P
    J Gastroenterol Hepatol; 2010 Feb; 25(2):362-8. PubMed ID: 19817958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural history of pruritus in primary biliary cirrhosis.
    Talwalkar JA; Souto E; Jorgensen RA; Lindor KD
    Clin Gastroenterol Hepatol; 2003 Jul; 1(4):297-302. PubMed ID: 15017671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of inflammatory bowel disease and ursodeoxycholic acid therapy on small-duct primary sclerosing cholangitis.
    Charatcharoenwitthaya P; Angulo P; Enders FB; Lindor KD
    Hepatology; 2008 Jan; 47(1):133-42. PubMed ID: 17992695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.